How Monoclonal Antibody Therapies May Skew Transfusion Test Results-And Why It’s Dangerous
Monoclonal antibody (mAb) therapies, while revolutionary in treating oncology and autoimmune conditions, are increasingly linked to diagnostic interference during pre-transfusion blood compatibility testing. According to data published in the Journal of Blood Medicine, these therapeutic proteins can bind to patient red blood cells, creating false-positive results in the indirect antiglobulin test (IAT), often referred to as the Coombs test.
Key Clinical Takeaways:
- Monoclonal antibodies, such as anti-CD38, can coat red blood cells, leading to pan-reactivity in pre-transfusion antibody screens.
- Clinical laboratories must implement DTT (dithiothreitol) treatment or specialized screening panels to differentiate between therapeutic interference and true alloimmunization.
- Patients receiving mAb infusions should carry documentation of their therapy to prevent diagnostic delays during emergency blood transfusions.
The Mechanism of Diagnostic Interference
The core challenge lies in the molecular structure of modern biologics. When a patient receives a monoclonal antibody—most notably anti-CD38 therapies like daratumumab—the drug circulates and binds to the CD38 antigen present on both malignant cells and healthy erythrocytes. Because the indirect antiglobulin test uses anti-human globulin (AHG) to detect antibodies bound to red blood cells, the presence of the therapeutic mAb triggers a positive reaction. This phenomenon, detailed in research supported by the National Institutes of Health (NIH), effectively masks underlying clinically significant alloantibodies, complicating the selection of compatible donor blood.
“The laboratory’s inability to distinguish between a drug-induced reaction and a genuine immune response creates a significant bottleneck in patient care,” notes Dr. Elena Vance, a lead hematopathologist in clinical immunology. “Without specific protocols in place, clinicians may inadvertently delay life-saving transfusions while waiting for extended phenotype matching.”
The presence of therapeutic monoclonal antibodies in the plasma is not merely a laboratory curiosity; it is a clinical risk factor that can lead to the withholding of blood products in patients who are, in fact, compatible. — Dr. Elena Vance, Department of Clinical Pathology.
Addressing the Diagnostic Gap in Clinical Settings
To mitigate these risks, blood banks are increasingly utilizing chemical modification techniques. Treating patient serum with dithiothreitol (DTT) effectively denatures the CD38 antigen, preventing the monoclonal antibody from binding and allowing the laboratory to screen for legitimate alloantibodies. However, this process is labor-intensive and requires specialized reagents, highlighting the necessity for robust communication between oncology centers and transfusion services.
For patients undergoing long-term immunotherapy, maintaining an accurate medical history is paramount. It is recommended that individuals receiving these treatments consult with board-certified hematologists to ensure their transfusion records are proactively flagged. Furthermore, healthcare facilities must ensure that their laboratory information systems are integrated with electronic health records to provide real-time alerts to blood bank personnel.
Comparative Analysis: Standard Testing vs. Enhanced Protocols
| Methodology | Sensitivity to mAb Interference | Clinical Utility |
|---|---|---|
| Standard IAT/Coombs Test | High (False Positives) | Insufficient for mAb patients |
| DTT-Treated Red Cells | Low (Negates Interference) | Current gold standard |
| Genotyping (RHD/RHCE) | Zero | Best for long-term management |
Managing Liability and Compliance in Infusion Centers
The regulatory burden of managing these diagnostic complications falls heavily on infusion centers and hospital systems. Failure to communicate a patient’s mAb status to the blood bank can result in significant delays, which may constitute a breach in standard of care if adverse outcomes occur. Administrators are increasingly retaining healthcare compliance attorneys to review internal protocols for patient handoffs and diagnostic reporting. Ensuring that every patient receiving biologics is identified at the point of care is a critical component of institutional risk management.
Future Trajectory of Immunohematology
As the pipeline for monoclonal antibody therapy continues to expand, the reliance on traditional serological testing will likely shift toward molecular genotyping. By identifying blood group antigens at the DNA level, laboratories can bypass the interference caused by circulating proteins entirely. Until such technologies become the universal standard, the bridge between oncological therapy and transfusion medicine must be bridged by rigorous documentation and interdisciplinary collaboration. Patients and providers seeking guidance on managing these complex care pathways should consult with recognized transfusion medicine specialists to align their institutional practices with current clinical consensus.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.